Small cell lung cancer transformation from EGFR-mutated lung adenocarcinoma: A case report and literatures review

References

• Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Eng J Med. 2009;361(10):947–57. doi:10.1056/NEJMoa0810699
   PubMed Web of Science ®Google Scholar
• Rossi A, Di Maio M. LUX-Lung: determining the best EGFR inhibitor in NSCLC? Lancet Oncol. 2015;16(2):118–9. doi:10.1016/S1470-2045(14)71196-9. PMID:25589190.
   PubMed Web of Science ®Google Scholar
• Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res. 2008;14(10):2895–9. doi:10.1158/1078-0432.CCR-07-2248. PMID:18483355.
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352(8):786–92. doi:10.1056/NEJMoa044238. PMID:15728811
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316(5827):1039–43. doi:10.1126/science.1141478. PMID:17463250.
   PubMed Web of Science ®Google Scholar
• Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka Y, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 2008;68(22):9479–87. doi:10.1158/0008-5472.CAN-08-1643. PMID:19010923.
   PubMed Web of Science ®Google Scholar
• Yamamoto C, Basaki Y, Kawahara A, Nakashima K, Kage M, Izumi H, Kohno K, Uramoto H, Yasumoto K, Kuwano M, et al. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Cancer Res. 2010;70(21):8715–25. doi:10.1158/0008-5472.CAN-10-0043. PMID:20959484.
   PubMed Web of Science ®Google Scholar
• Suda K, Tomizawa K, Fujii M, Murakami H, Osada H, Maehara Y, Yatabe Y, Sekido Y, Mitsudomi T. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol. 2011;6(7):1152–61. doi:10.1097/JTO.0b013e318216ee52. PMID:21597390.
   PubMed Web of Science ®Google Scholar
• Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 2015;16(4):e165–172. doi:10.1016/S1470-2045(14)71180-5. PMID:25846096.
   PubMed Web of Science ®Google Scholar
• Jiang SY, Zhao J, Wang MZ, Huo Z, Zhang J, Zhong W, Xu Y. Small-cell lung cancer transformation in patients with pulmonary adenocarcinoma: A case report and review of literature. Medicine. 2016;95(6):e2752. doi:10.1097/MD.0000000000002752. PMID:26871823.
   PubMed Web of Science ®Google Scholar
• Roca E, Gurizzan C, Amoroso V, Vermi W, Ferrari V, Berruti A. Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: A systematic review and pooled analysis. Cancer Treat Rev. 2017;59:117–22. doi:10.1016/j.ctrv.2017.07.007. PMID:28806542.
   PubMed Web of Science ®Google Scholar
• Shi X, Duan H, Liu X, Zhou L, Liang Z. Genetic alterations and protein expression in combined small cell lung cancers and small cell lung cancers arising from lung adenocarcinomas after therapy with tyrosine kinase inhibitors. Oncotarget. 2016;7(23):34240–9. doi:10.18632/oncotarget.9083. PMID:27145273.
   PubMedGoogle Scholar
• Niederst MJ, Sequist LV, Poirier JT, Mermel CH, Lockerman EL, Garcia AR, Katayama R, Costa C, Ross KN, Moran T, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat commun. 2015;6:6377. doi:10.1038/ncomms7377. PMID:25758528.
   PubMed Web of Science ®Google Scholar
• Lee JK, Lee J, Kim S, Kim S, Youk J, Park S, An Y, Keam B, Kim DW, Heo DS, et al. Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas. J clin oncol. 2017;35(26):3065–74. doi:10.1200/JCO.2016.71.9096. PMID:28498782.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li XY, Tang Y, Xu Y, Guo WH, Li YC, Liu XK, Huang CY, Wang YS, Wei YQ. Rapid increase of serum neuron specific enolase level and tachyphylaxis of EGFR-tyrosine kinase inhibitor indicate small cell lung cancer transformation from EGFR positive lung adenocarcinoma? Lung Cancer. 2013;81(2):302–5. doi:10.1016/j.lungcan.2013.04.005. PMID:23683536.
   PubMed Web of Science ®Google Scholar
• Norkowski E, Ghigna MR, Lacroix L, Le Chevalier T, Fadel É, Dartevelle P, Dorfmuller P, Thomas de Montpréville V. Small-cell carcinoma in the setting of pulmonary adenocarcinoma: new insights in the era of molecular pathology. J Thor Oncol. 2013;8(10):1265–71. doi:10.1097/JTO.0b013e3182a407fa
   PubMed Web of Science ®Google Scholar
• van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet. 2011;378(9804):1741–55. doi:10.1016/S0140-6736(11)60165-7. PMID:21565397.
   PubMed Web of Science ®Google Scholar
• Ahn S, Hwang SH, Han J, Choi YL, Lee SH, Ahn JS, Park K, Ahn MJ, Park WY. Transformation to small cell lung cancer of pulmonary adenocarcinoma: Clinicopathologic analysis of six cases. J Pathol Transl Med. 2016;50(4):258–63. doi:10.4132/jptm.2016.04.19. PMID:27160687.
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Ikushima S, Ono R, Awano N, Kondo K, Furuhata Y, Fukumoto K, Kumasaka T. Transformation to small-cell lung cancer as a mechanism of acquired resistance to crizotinib and alectinib. Jpn J Clin Oncol. 2016;46(2):170–3. PMID:26613679.
   PubMed Web of Science ®Google Scholar
• Imakita T, Fujita K, Kanai O, Terashima T, Mio T. Small cell lung cancer transformation during immunotherapy with nivolumab: A case report. Respir Med Case Rep. 2017;21:52–5. PMID:28393006.
   PubMed Web of Science ®Google Scholar